OncoCyte Corporation investor relations material

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. Its tests apply genetic analysis technology to advance early detection of cancer. The company's lead product candidates are Circulating Tumor Cell (CTC), a blood test to detect lung cancer; and DetermaIO, a bioinformatic analysis software that provides interpretative information on the outputs from various types of assays, including CTC. It is also developing DetermaVu, a cell free DNA blood test for detecting various types of lung cancer; DetermaSolver, a proprietary technology.